In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Sientra Inc. (medical aesthetic devices) netted $108mm through the public offering of 20mm shares (including the overallotment) at $5.75. The company will use the proceeds to carry out sales and marketing initiatives, expand commercially in the US and globally, and fund R&D. Potentially, some of the funds may also support future acquisitions or investments in complementary businesses, products, or technologies. Sientra offers both a portfolio of breast products (including implants, tissue expanders, and scar management products sold to plastic surgeons) as well as the miraDry system (for reduction of underarm sweat, odor, and hair), with a 2019 sales outlook of $44-46mm and $35-37mm for the segments, respectively.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?